Merck & Co Inc
NYSE: MRK
$114.96
-$0.67 (-0.6%)
Real Time Data Delayed 15 Min.
MRK Articles
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite. We have heard enough names around this diabetes treatment...
Published:
Last Updated:
The 10-year Treasury hit yet another record low under 1.6% today and stocks are in the tank again due to poor economic data. Europe continues to face a meltdown and the hope is for a rate cut out...
Published:
Last Updated:
A stock market that sells off eight of nine days is not a good market. Even the Facebook IPO is being viewed as a one-off item rather than a systemic item which will make the market stronger. ...
Published:
Last Updated:
Blame whatever you want. A weaker U.S. economy, a weakening and flailing Europe, a move to socialism in France and Greece, a weaker BRIC and emerging market story, commodity prices and on and...
Published:
Last Updated:
Markets opened higher this morning following a lower-than-expected GDP growth estimate of 2.2%. That was weaker, but not awful (our coverage here). The consumer sentiment survey rose a couple of...
Published:
Last Updated:
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is supposed to be acquired by a larger drug company. It is one of the biggest public merger rumors out there. At least that is the belief of Wall...
Published:
Last Updated:
How many DJIA components can raise their dividend in one week? Johnson & Johnson (NYSE: JNJ) answered that question as “Who knows, but we can make it one more!” J&J has joined the...
Published:
Last Updated:
Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to acquire the company. With another small-cap to mid-cap biotech and...
Published:
Last Updated:
Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer from...
Published:
Concerns about Spain and Italy renew capital markets’ rejection of area debt. (Reuters) Best Buy (NYSE: BBY) will have to bring in an outsider to change the company’s old philosophy. (Reuters)...
Published:
Canadian-based drug company Cardiome Pharma Corp. (NASDAQ: CRME) announced this morning that Merck & Co. Inc. (NYSE: MRK) has cancelled further development of an oral version of a Cardiome drug...
Published: